[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Third Xiangya Hospital of Central South University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":573},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,42,72,98,117,138,160,183,208,229,255,274,296,324,345,369,395,416,437,456,476,501,520,539,555],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642819","phase-2-efficacy-and-safety-of-induction-benmelstobart-plus-anlotinib-and-chemotherapy-followed-by-concurrent-chemoradiotherapy-and-benmelstobart-maintenance-versus-concurrent-chemoradiotherapy-followed-by-benmelstobart-maintenance-in-patients-with-unresectable-stage-iii-nsclc-100642819",false,"NCT07643350","Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC","Comparison of the Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC: A Randomized, Controlled, Multicenter Phase II Clinical Study","Inclusion Criteria:\n\n* 1\\. Voluntary signing of a written ICF.\n* 2\\. Age at enrollment: 18-75 years; both sexes are eligible.\n* 3\\. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 or 1.\n* 4\\. Expected survival: ≥3 months.\n* 5\\. Histologically or cytologically confirmed stage III NSCLC (classified according to the International Union Against Cancer and the American Joint Committee on Cancer's 9th edition of the lung cancer TNM staging system).\n* 6\\. Definitively determined as unresectable after MDT discussion.\n* 7\\. The primary driver genes must not harbor sensitive mutations (including EGFR (exon 19 deletion, exon 21 L858R point mutation, exon 20 insertion, etc.), ALK fusion, ROS1 fusion, MET exon 14 skipping mutation, HER2 exon 20 mutation, BRAF V600E mutation, RET fusion, NTRK fusion). For non-squamous NSCLC, a prior tissue-based common genetic testing report must be provided; otherwise, tumor tissue samples (archived or fresh, primary or metastatic) must be collected prior to enrollment for genetic mutation status assessment (at a local laboratory or central laboratory). For squamous NSCLC subjects with a smoking history or current smoking status, if the prior primary driver gene mutation status is unknown, no corresponding testing is required prior to enrollment, and the status shall be considered negative.\n* 8\\. No prior systemic antitumor therapy or chest radiotherapy for NSCLC.\n* 9\\. At least one measurable lesion according to RECIST v1.1, and such lesions must be suitable for repeated accurate measurement per RECIST v1.1 criteria. -10. Subjects must provide tumor tissue samples diagnosed as locally advanced tumors at the time of diagnosis or thereafter, including archived or freshly obtained uncolored formalin-fixed paraffin-embedded (FFPE) pathological sections (preferably recently obtained tumor tissue samples), approximately 10-25 sections (of which approximately 10-15 sections are required for EGFR and ALK testing, and approximately 10 sections for PD-L1 expression testing; however, additional sections must be provided if the central laboratory determines that the sample is insufficient for testing), or fresh tumor tissue specimens (frozen in liquid nitrogen for omics research). Tumor lesions used for fresh biopsy should not be designated as RECIST v1.1 target lesions unless the lesion is the only measurable lesion. For archived samples, collection must occur after the last systemic treatment, and the collection site must not have undergone radiotherapy. Note: If a subject's archived sample does not meet the above requirements, the investigator may determine that the biopsy does not serve the subject's best interests and may, after discussion with the project team, permit the use of the archived sample.\n* 11.Fertile female subjects must have undergone a urine or serum pregnancy test within 7 days prior to the first medication administration (if the urine pregnancy test result is not negative, a serum pregnancy test must be performed, with the serum result serving as the definitive determination), and the result must be negative. If a fertile female subject has sexual intercourse with an unmarried male partner, she must have used an acceptable contraceptive method since the start of screening and must agree to continue using contraception for 120 days after the last administration of the antitumor drug; whether contraception should be discontinued after this period should be discussed with the investigator.\n* 12\\. If an unmarried male subject has sexual intercourse with a fertile female partner, he must have used an effective contraceptive method from the start of screening until 120 days after the last administration; whether contraception should be discontinued after this time point should be discussed with the investigator.\n* 13\\. The subject must be willing and able to comply with all scheduled visits, treatment regimens, laboratory tests, and other study requirements.\n\nExclusion Criteria:\n\n* 1\\. Histopathological presence of any small cell carcinoma components, as well as specific types such as salivary gland type and SMARCA4 deletion.\n* 2\\. Except for NSCLC, the subject had suffered from other malignancies within the preceding 5 years. Subjects who have been cured of other tumors through local treatment (e.g., basal or squamous cell carcinoma of the skin, superficial bladder cancer, cervical or breast carcinoma in situ) are not excluded.\n* 3\\. Concurrent enrollment in another clinical study, unless it is an observational, non-interventional clinical study or a follow-up phase of an intervention study.\n* 4\\. Previous local treatments targeting the tumor lesion, such as thoracic radiotherapy or radiofrequency ablation.\n* 5\\. Receiving nonspecific immunomodulatory therapy (e.g., interleukins, interferons, thym peptides, tumor necrosis factor, etc., excluding IL-11 for thrombocytopenia) within 2 weeks prior to the first dose; or receiving herbal or proprietary Chinese medicines with antitumor indications within 1 week prior to the first dose.\n* 6\\. Suffering from an active autoimmune disease requiring systemic treatment within the past two years (e.g., treatment with disease-modifying drugs, corticosteroids, or immunosuppressants). Alternative therapies (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) are not considered systemic treatments.\n* 7\\. History of immunodeficiency; positive HIV antibody test; or current long-term use of systemic corticosteroids or other immunosuppressants.\n* 8\\. Subjects with known active tuberculosis (TB) or suspected active TB require clinical examination for exclusion; known active syphilis infection.\n* 9\\. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* 10\\. Non-infectious pneumonia\u002Finterstitial lung disease requiring systemic glucocorticoid therapy within the past 5 years or currently.\n* 11.Severe infections occurring within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infections treated with systemic anti-infective therapy within 2 weeks prior to the first dose (excluding antiviral therapy for hepatitis B or hepatitis C).\n* 12.Subjects with active Hepatitis B (Hepatitis B surface antigen \\[HBsAg\\] positive AND Hepatitis B virus DNA \\[HBVDNA\\] \\>1,000 copies\u002FmL \\[200IU\u002FmL\\] or above the lower limit of detection); note that HBsAg-positive subjects are required to receive antiviral therapy against Hepatitis B during the study treatment period. Subjects with active Hepatitis C (Hepatitis C virus \\[HCV\\] antibody positive AND HCV RNA levels above the lower limit of detection).\n* 13Has undergone major surgical procedures or sustained severe trauma within 30 days prior to the first dose administration, or plans to undergo major surgery within 30 days after the first dose (as determined by the investigator); has undergone minor local surgeries within 3 days prior to the first dose administration (excluding peripheral venous catheterization and intravenous infusion port implantation).\n* 14\\. The tumor invades or compresses surrounding vital organs (e.g., aorta, heart and pericardium, superior vena cava, trachea, esophagus) or carries a risk of esophageal-tracheal fistula or esophageal-plenic fistula; mediastinal lymph node metastasis involves the trachea or main bronchi with a risk of bronchial fistula.\n* 15\\. Currently has uncontrolled comorbid conditions, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or psychiatric\u002Fsocial conditions that may limit the subject's adherence to study requirements or affect their capacity to provide written informed consent.\n* 16\\. Has a history of myocarditis, cardiomyopathy, or malignant arrhythmias; experienced unstable angina, myocardial infarction, congestive heart failure, or vascular diseases (e.g., aneurysm with rupture risk) requiring hospitalization within 12 months prior to the first dose; or has other cardiac injuries that may affect the safety evaluation of antineoplastic agents.\n* 17\\. History of esophageal and gastric varices, severe ulcers, non-healed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose; or acute exacerbation of chronic obstructive pulmonary disease within 1 month prior to the first dose.\n* 18\\. History of any arterial thromboembolic event, venous thromboembolic event of grade 3 or higher per NCI CTCAE 5.0 criteria, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to the first dose; or current hypertension with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite oral antihypertensive therapy.\n* 19.Patients with a history of severe bleeding tendency or coagulation disorders; those with clinically significant hemoptysis (defined as coughing up or expectorating ≥ 1 teaspoon of fresh blood or small blood clots or only blood without sputum, patients with blood in sputum are allowed to be enrolled) within 1 month before the first administration; those with imaging findings during the screening period showing that the tumor encircles important blood vessels or has obvious necrosis or cavities, and the investigator determines that participation in the study would pose a risk of bleeding.\n* 20\\. Received a live vaccine within 30 days prior to the first dose, or plans to receive a live vaccine during the study period.\n* 21\\. Known hypersensitivity to any component of any antineoplastic agent; history of severe hypersensitivity reactions to other monoclonal antibodies.\n* 22\\. Known history of mental illness, drug abuse, alcoholism, or substance use.\n* 23\\. Women who are pregnant or breastfeeding.\n* 24\\. Any past or current medical conditions, treatments, or laboratory abnormalities that may confound study results, compromise the participant's ability to complete the study, or make participation potentially detrimental to the participant's best interests.\n* 25\\. Localized or systemic diseases not caused by malignancies, or tumor-related conditions or symptoms, that may pose significant medical risks and\u002For uncertainty in survival assessment, such as tumor-associated leukemic response (white blood cell count\\>20 × 10⁹\u002FL) or cachectic manifestations (e.g., known weight loss exceeding 10% within three months prior to screening).","ALL","18 Years","75 Years",{"count":21,"type":22},152,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to compare the efficacy and safety of induction Benmelstobart plus Anlotinib and chemotherapy followed by concurrent chemoradiotherapy (CCRT) and subsequent Benmelstobart maintenance versus CCRT followed by Benmelstobart maintenance in patients with unresectable stage III NSCLC. Additionally, high-throughput sequencing and multi-omics analysis will be performed on patient-derived tissue and blood samples. By integrating baseline characteristics with clinical data, we aim to identify key determinants of treatment efficacy and prognosis, thereby establishing a precision evaluation system for therapeutic outcomes.",[28],"NSCLC","NOT_YET_RECRUITING","2026-06-08",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":22},"2026-05-15",{"date":37,"type":22},"2031-05-15",{"name":39,"class":40},"The Third Xiangya Hospital of Central South University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100643177","a-large-scale-prospective-cohort-study-was-conducted-to-explore-the-association-between-environmental-exposure-and-behavioral-factors-and-infertility-the-success-rate-of-assisted-reproductive-technology-100643177","NCT07641387","A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology)","Inclusion Criteria:\n\n* 1\\. Women aged 18 to 46 who use their own eggs or men aged 18 to 55 who use their own sperm; 2. Patients who meet the diagnostic criteria for infertility; 3. Clarify the medical history of persistent infertility for a certain period of time; 4. Voluntarily participate in the project and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Artificial insemination population with any of the following ARTs contraindications: a. Impairment of sperm and egg combination caused by fallopian tube factors on the female side. b. The female side suffers from acute infection of the reproductive and urinary system or sexually transmitted diseases. c. The female side suffers from genetic diseases, serious physical diseases, and mental and psychological disorders. d. There is a history of birth of babies with congenital defects and it is confirmed that it is caused by female factors. e. The female side is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. f. The female side has bad habits such as alcoholism and drug abuse.\n\n  2\\. First-generation test-tube baby and second-generation test-tube baby population with any of the following ARTs contraindications: a. Any party who provides gametes suffers from acute infection of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism and drug abuse. b. Any party who provides gametes is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. c. The couple who received embryo donation\u002Fegg donation suffers from acute infection of reproductive and urinary system and sexually transmitted diseases, or has bad habits such as alcoholism and drug abuse. d. The woman's uterus is not capable of pregnancy or has a serious physical disease that cannot withstand pregnancy.\n\n  3\\. No embryo transfer after egg retrieval; 4. Frozen embryo transfer is received more than 180 days after egg retrieval.","55 Years",{"count":50,"type":22},5000,[52],"NA","The aim is to explore the reasons for the failure of assisted reproductive technology (ART) in infertile patients in Hunan Province and seek ways to improve the success rate of ART. The study will focus on how environmental exposure (such as environmental pollutants related to plastic products) and lifestyle and social factors affect the success rate of ART in infertile patients.\n\nIn order to explore these issues in depth, the study plans to collect 5,000 samples (male: female ratio 1:1), screen the research subjects from infertile patients who visited Xiangya Third Hospital in Changsha, Hunan Province, and establish a large-scale, prospective infertility patient cohort. By collecting multi-faceted information of the research subjects, including sociodemographic characteristics, lifestyle, basic health status, etc., and conducting long-term follow-up observations, the ART live birth situation of infertile patients is analyzed.\n\nIn terms of research methods, a multivariate analysis method will be used to explore the association between various factors and ART success rate, and a risk prediction model will be constructed. In addition, the study also hopes to clarify the specific reasons for the failure of infertile patients to receive ART, provide a scientific basis for clinical decision-making, and provide guidance for the formulation of environmental protection policies and the improvement of public reproductive health literacy.\n\nIn general, this study, through a large-scale, prospective cohort study, deeply explores the various factors that affect the success rate of ART in infertile patients, and strives to build a risk prediction model in order to improve the success rate of ART and bring more hope to infertile families.",[55,56,57],"Infertility","Infertility Assisted Reproductive Technology","Infertility (IVF Patients)",[59,60,61,62,63,64],"environmental pollutants","Assisted Reproductive Technology","prospective cohort","life-style","risk factor","social factor","RECRUITING",{"date":32,"type":33},{"date":68,"type":33},"2025-04-01",{"date":70,"type":22},"2035-04-01",{"name":39,"class":40},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100639302","a-multicenter-prospective-randomized-controlled-clinical-study-on-the-effect-of-hysteroscopic-uterine-septum-resection-on-ivf-et-outcomes-in-infertile-patients-with-non-recurrent-miscarriage-100639302","NCT07611656","A Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on IVF-ET Outcomes in Infertile Patients With Non-recurrent Miscarriage","Inclusion Criteria:\n\n* (1) Meet the 2024 ASRM diagnostic criteria for uterine septate after 3D color Doppler ultrasound examination; (2) Aged between 20 and 40 years old; (3) Meet the diagnosis of infertility: those who have had regular sexual intercourse for at least 12 months but have not achieved clinical pregnancy; (4) Plan to undergo IVF\u002FICSI (non-PGD); (5) Sign the informed consent form and be able to accept and adhere to treatment and follow-up.\n\nExclusion Criteria:\n\n* (1) Recurrent miscarriage; (2) Combined with untreated intramural uterine fibroids larger than 3 cm, intrauterine adhesions with an AFS score of ≥5 points; (3) Uncontrolled endocrine disorders, such as abnormal thyroid function (FT3, FT4 abnormal), hyperprolactinemia (greater than 2 times the upper limit of normal), combined with atypical endometrial hyperplasia or malignant lesions, acute inflammation of the reproductive system, coagulation dysfunction, etc.; if combined with endometrial polyps or submucosal fibroids, they can still be included in the group after resection; (4) Combined with adenomyosis (uterine body\\>50 days of pregnancy), chocolate cysts with a diameter of\\>4 cm, or severe dysmenorrhea and clear DIE lesions (diameter\\>1 cm) can be palpated by gynecological triple examination; (5) Untreated severe hydrosalpinx (diameter\\>3 cm) or hydrosalpinx with reflux confirmed by ultrasound; (6) Other important organ diseases and other surgical contraindications or relative contraindications; other conditions that are not suitable for assisted reproductive treatment; (7) Have participated in other interventional clinical studies (within the last three months).","FEMALE","20 Years","40 Years",{"count":82,"type":22},236,[52],"This study aims to evaluate the impact of hysteroscopic transcervical resection of the septum (TCRS) on fertility in infertile women without recurrent miscarriage, primarily assessing its effect on subsequent IVF-ET outcomes. The research attempts to answer: for infertile women with uterine septum planning to undergo IVF\u002FICSI (excluding preimplantation genetic diagnosis), does TCRS improve pregnancy outcomes (such as live birth rate, pregnancy rate, miscarriage rate, etc.) compared to non-surgical treatment (conservative observation), and to clarify the clinical value and safety of this surgical intervention.",[86],"Infertility and Miscarriage",[88,89],"transcervical resection of septum","In Vitro Fertilization and Embryo Transfer","2026-05-20",{"date":92,"type":33},"2026-05-28",{"date":94,"type":33},"2025-06-01",{"date":96,"type":22},"2030-06-01",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100639961","to-evaluate-the-safety-and-effectiveness-of-intrauterine-adhesion-preventer-in-the-prevention-and-treatment-of-intrauterine-adhesions-a-prospective-multicenter-randomized-controlled-clinical-trial-100639961","NCT07611474","To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients clinically diagnosed with intrauterine adhesions and with surgical indications (referring to those with fertility requirements or obstructed menstrual blood drainage) ② Women aged 20-40 years old; ③ Subjects voluntarily participated in the trial and signed informed consent.\n\nExclusion Criteria:\n\n* ① Patients with obviously abnormal uterine cavity shape after surgery; those who could not clearly separate the normal uterine cavity anatomical morphology (i.e. bilateral or unilateral fallopian tube openings were not visible); those with reproductive organ malformations and uterine cavities that were too large or too small; those with recent uterine perforation; those with cervical insufficiency.\n\n  * Those with a history of intrauterine adhesions and treatment;\n\n    * Those with endometrial tuberculosis or suspected endometrial tuberculosis;\n\n      * Those with adenomyosis or uterine fibroids\\>4cm;\n\n        * Those with a history of malignant tumors or suspected malignant tumors;\n\n          * Those with acute and chronic intrauterine infection and genital infection;\n\n            * Those with unexplained vaginal bleeding or suspected uterine malignant lesions;\n\n              * Those with severe anemia and abnormal coagulation function; those with a history of thrombosis; ⑨ Those in the acute stage of various diseases or severe systemic diseases;\n\n                * Those with severe mental illness and physical weakness who cannot tolerate this operation;\n\n                  ⑪ Those with severe heart, liver, and kidney function diseases;\n\n                  ⑫ Those with contraindications to anesthesia or surgery;\n\n                  ⑬ Those who have participated in clinical trials in the past three months.\n                  * Those who are considered unsuitable for inclusion by the researchers.",{"count":105,"type":22},200,[52],"To evaluate the effect of uterine stents in preventing intrauterine adhesions after intrauterine operation and whether they meet the safety requirements for clinical use. The trial adopted a prospective, multicenter, randomized controlled, non-inferiority clinical trial design. The target population of the trial was 200 women aged 20-40 years with intrauterine adhesions and surgical indications (referring to those with fertility requirements or menstrual blood drainage obstruction), who were randomly divided into an experimental group and a control group, with 100 cases in each group. The experimental group was the group with intrauterine stents placed in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery, and the control group was the group with intrauterine rings + balloons + sodium hyaluronate gel placed in the uterine cavity. After 3 courses of artificial cycles, the patients were hospitalized for hysteroscopy review.",[109,110],"Intrauterine Adhesion","Intrauterine Adhesions",{"date":92,"type":33},{"date":113,"type":33},"2021-01-01",{"date":115,"type":22},"2031-12-31",{"name":39,"class":40},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100628907","phase-2-research-of-traditional-chinese-medicine-oral-preparation-of-c-cicadae-in-the-treatment-of-als-patients-with-elevated-plasma-sphingolipids-100628907","NCT07467746","Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","Single-center Study of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","Inclusion Criteria:\n\n* Patients with ALS diagnosed according to the revised El Escorial criteria.\n* Significantly elevated plasma levels of key SL molecules (e.g., Cer(d18:0\u002F24:0), Cer(d18:1\u002F22:0), and other relevant molecules), meeting the predefined cut-off values for metabolic stratification.\n* Time from disease onset to enrollment ≤24 months\n* For participants receiving riluzole and\u002For edaravone, the dose must have been stable for at least 30 days prior to enrollment.\n* Male or non-pregnant, non-lactating female patients, aged \\> 18 and ≤ 80 years old.\n* Voluntarily participate in clinical trials, sign informed consent, and be able to understand and abide by research procedures.\n\nExclusion Criteria:\n\n* Presence of peripheral neuropathy or motor neuron injury attributable to other clearly defined etiologies and sufficient to interfere with disease classification in this study, including but not limited to vitamin deficiency, toxic neuropathy, drug- or chemotherapy-related neuropathy, alcoholic neuropathy, paraneoplastic syndrome, autoimmune neuropathy, and infection-related neuropathy;\n* Severe hepatic or renal dysfunction that may affect the safety evaluation of the investigational product or the interpretation of metabolomics results;\n* Severe cardiopulmonary dysfunction, active infection, active malignancy, or other major systemic diseases that, in the opinion of the investigator, may significantly affect prognosis assessment or completion of follow-up;\n* Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period;\n* Participation in another interventional clinical trial within 30 days prior to enrollment, or being within the washout period of another investigational product;\n* Inability to comply with clinical assessments, sample collection, or follow-up procedures;\n* Persistent high dependence on noninvasive ventilation (\\>16 hours\u002Fday), or advanced respiratory failure as judged by the investigator, such that the participant is unable to complete oral intervention and efficacy evaluation;\n* Severe dysphagia, gastrointestinal dysfunction, or other conditions rendering the participant unable to tolerate oral administration;\n* Known allergy to C. cicadae preparations, fungal products, or any of their excipients;\n* Concomitant diseases or conditions that may substantially affect motor function assessment and thereby interfere with evaluation of the primary endpoint;\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for study participation.","80 Years",{"count":126,"type":22},84,[25],"Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to progressive muscle weakness and functional decline. This study is designed as a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of an oral preparation of C. cicadae in patients with sporadic ALS and elevated plasma sphingolipid (SL) levels. Efficacy will be assessed primarily by changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score and plasma SL levels.Participants who meet the eligibility criteria and provide written informed consent will be randomly assigned in a 1:1 ratio to either the C. cicadae treatment group or the placebo group. The treatment group will receive oral C. cicadae at a dose of 0.1 g\u002Fkg\u002Fday (dry weight), administered in three divided doses per day. The placebo group will receive a matched placebo with a similar appearance and odor, administered according to the same schedule. A total of approximately 84 participants will be enrolled. The intervention period will be 6 months, and participants will be followed for a total of 9 months.",[130],"Amyotrophic Lateral Sclerosis","2026-05-17",{"date":90,"type":33},{"date":134,"type":22},"2026-04",{"date":136,"type":22},"2027-04",{"name":39,"class":40},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100640505","dp-dct-10a-comparative-clinical-study-on-the-effect-of-dapagliflozin-combined-with-cgm-versus-smbg-on-glycemic-control-in-patients-with-type-2-diabetes-mellitus-based-on-the-dp-dct-platform-100640505","NCT07595289","DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform","A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform","DP DCT","Inclusion Criteria:\n\n* Voluntarily agree to participate in the study and sign the informed consent form; Age between 18 and 60 years (inclusive), both genders; Diagnosed with T2DM within 5 years and have not received any glucose-lowering medication in the past 3 months, with HbA1c ≥ 7% and ≤ 9%; Willing and able to maintain a stable lifestyle in terms of diet and exercise throughout the study period; Able to properly operate a smartphone, CGM, SMBG, smart scale, and smart wristband under the guidance and training of the investigator; During the CGM run-in period, obtain at least 70% data availability from the participants.\n\nExclusion Criteria:\n\n* Diagnosed with or suspected of having type 1 diabetes mellitus, monogenic diabetes, or secondary diabetes; Experienced acute complications of diabetes (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, etc.) within 3 months prior to screening;\n\nSevere comorbidities or medical history:\n\n1. Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg);\n2. Congestive heart failure (NYHA class III-IV);\n3. Severe hepatic or renal impairment (ALT\u002FAST \\> 3 × ULN, eGFR \\\u003C 30 mL\u002Fmin);\n4. Malignant tumors, autoimmune diseases, severe infections, gastroparesis or other severe gastrointestinal diseases, hematological disorders;\n5. History of recurrent genitourinary tract infections; Alcohol abuse or alcoholic liver disease; Known or suspected allergy to SGLT-2 inhibitors (e.g., dapagliflozin) or medical adhesives; Received glucose-lowering medication within the past 3 months; Pregnant or breastfeeding women, or women planning to become pregnant during the study period; Presence of any medical, psychological, social, or geographical factors that, in the investigator's judgment, may compromise participant safety or interfere with the assessment of study outcomes.",{"count":147,"type":22},120,[52],"The goal of this clinical trial is to:\n\n1\\) evaluate the feasibility of conducting decentralized clinical trials (DCT) in collaboration with community resources; 2) test the reliability of a self-developed Digital Platform for Decentralized Clinical Trials (DP-DCT); and 3) compare the effect of two different glucose monitoring methods on glycemic control in patients with type 2 diabetes mellitus (T2DM). The study population consists of adults with T2DM who do not have acute diabetic complications.\n\nThe main questions it aims to answer are:\n\nIs it feasible to conduct a DCT in collaboration with community settings across key steps such as participant recruitment, informed consent, drug delivery, and remote monitoring?\n\nCan the DP-DCT platform reliably achieve full electronic integration from participant recruitment to statistical reporting, and automatically generate verified electronic copies of key source data in real time?\n\nIn patients taking dapagliflozin, does continuous glucose monitoring (CGM) lead to a higher rate of glycemic control target achievement compared to traditional self-monitoring of blood glucose (SMBG)?\n\nResearchers will compare the CGM group (dapagliflozin + CGM) and the SMBG group (dapagliflozin + SMBG) to see if there is a difference in the rate of achieving glycemic control targets after 12 weeks of treatment.\n\nParticipants will:\n\nWear a blinded CGM device for 7days before starting treatment (run-in period) to assess eligibility for randomization.\n\nTake dapagliflozin (10 mg once daily) and maintain healthy lifestyle habits.\n\nMonitor their blood glucose using either a CGM device or a traditional glucose meter according to their group assignment.\n\nWear a smart bracelet and use a smart weight scale, with all data automatically uploaded via the DP-DCT platform.\n\nWear a blinded CGM device again for 7 days after the 12-week treatment period (follow-up period).\n\nComplete most study procedures (including informed consent, drug receipt, and follow-up communication) through an online platform without frequent hospital visits, with some tasks supported by community hospitals.",[151],"Type 2 Diabetes Mellitus (T2DM)","2026-05-12",{"date":154,"type":33},"2026-05-19",{"date":156,"type":22},"2026-08-01",{"date":158,"type":22},"2027-08-01",{"name":39,"class":40},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},"100620106","phase-3-a-clinical-trial-evaluating-the-efficacy-safety-and-pharmacokinetic-profile-of-trd303-for-postoperative-analgesia-after-abdominal-surgery-in-china-100620106","NCT07353307","A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China.","To Evaluate the Efficacy, Safety and Pharmacokinetics of TRD303 Solution for Postoperative Analgesia After Abdominal Surgery in a Multicenter, Randomized, Double-blind, Placebo-positive Controlled Phase Ⅲ Clinical Trial","Inclusion Criteria:\n\n1. Fully understand the purpose and significance of this study, voluntarily participate in this study, voluntarily sign the informed consent, and voluntarily abide by the process of this study;\n2. 18 years old ≤ age ≤80 years old, regardless of gender; 18.0kg\u002Fm2≤BMI≤30.0kg\u002Fm2, ≥50.0kg for men and ≥45.0kg for women;\n\n4\\. American Society of Anesthesiologists (ASA) grade I-II (Appendix 1); (5) Elective abdominal surgery under general anesthesia, including laparoscopic or open surgery, and the length of the main incision is expected to be between 7±2cm (including the boundary value at both ends); 6. Can understand the research process and the use of various scales involved in this study, and can effectively communicate with researchers.\n\nExclusion Criteria:\n\n1. Those who are known to have allergies or contraindications to ropivacaine or other amide local anesthetics, inactive ingredients of the investigational drug, or other drugs that may be used during the trial, and who are judged by the investigator to be unsuitable for the trial;\n2. Use of the following drugs for less than 5 half-lives before randomization (according to the actual drug instructions, the half-life is unknown, or eluted according to 48 hours), including but not limited to: Class III antiarrhythmic drugs, glucocorticoids (systemic), anticonvulsants, sedative-hypnotic drugs, anxiolytic drugs, antidepressant drugs, CYP1A2 enzyme inhibitor, sedative drugs (except those used according to the protocol), analgesic drugs (except those used according to the protocol), the specific types refer to the list of prohibited drugs; Use of Chinese herbal medicine with definite analgesic effect assessed by investigators within 7 days before randomization;\n3. Participants who planned to use hyperthermic perfusion, intraperitoneal chemotherapy, physical therapy, or other concomitant therapies during the treatment period that the investigator judged might affect postoperative pain;\n4. patients who underwent abdominal surgery within 1 year before signing ICF;\n5. patients who planned to undergo surgery at other sites during the study period;\n6. Combined with other pain conditions that may confound the evaluation of postoperative pain according to the investigator;\n7. Participants with a history of congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency;\n8. Previous and\u002For family history of malignant hyperthermia;\n9. Participants with poorly controlled blood pressure during screening (systolic blood pressure ≥160mmHg or ≤90 mmHg while sitting during screening, and\u002For diastolic blood pressure ≥100 mmHg or ≤60mmHg during screening, excluding abnormal blood pressure during anesthesia), whose abnormalities were judged by the investigator to be clinically significant and increase perioperative risk;\n10. Heart rate \\\u003C 50 beats\u002Fmin or heart rate \\> 100 beats\u002Fmin during screening (excluding abnormal heart rate during anesthesia), and the abnormal heart rate was judged by the investigator to be clinically significant; QTcF \\> 450ms in men and \\> 470ms in women \\[QTcF=QT\u002F (RR\\^0.33)\\]; Or a history of severe arrhythmias such as atrioventricular block of degree II or higher, or cardiac insufficiency;\n11. Patients with severe liver, kidney, cardiovascular, cerebrovascular, or metabolic diseases judged by the investigator to be unsuitable for the trial;\n12. Patients with advanced malignant tumors who were judged by the investigators to be not suitable for participating in the trial;\n13. Patients with a history of mental diseases (such as schizophrenia, depression, etc.), dementia, migraine, or epilepsy, who were judged by the investigator to be unfit for the trial;\n14. Patients with skin infection, ulceration or scar constitution around the incision, judged by the investigator to be not suitable for the trial;\n15. Participants with a history of psychoactive and narcotic drug abuse, drug use, and heavy drinking (i.e., drinking an average of more than 2 units of alcohol per day (1 unit =360mL of beer or 45mL of 40% liquor or 150 ml of wine) in the year before randomization;",{"count":168,"type":22},333,[170],"PHASE3","A multicenter, randomized, double-blind, placebo-positive, parallel-controlled, phase Ⅲ clinical trial of the efficacy, safety and pharmacokinetics of TRD303 solution for postoperative analgesia in patients undergoing abdominal surgery was conducted. The primary objective was to evaluate the efficacy of TRD303 solution for postoperative analgesia after abdominal surgery. The secondary objective was to evaluate the safety and pharmacokinetic profile of TRD303 solution for postoperative analgesia after abdominal surgery.",[173],"Pain After Abdominal Surgery","2026-03-25",{"date":176,"type":33},"2026-03-27",{"date":178,"type":33},"2025-12-30",{"date":180,"type":22},"2026-12-30",{"name":39,"class":40},2,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":41},"100603610","phase-2-the-efficacy-and-safety-of-the-combination-of-pd-1-with-chemotherapy-and-adaptive-radiotherapy-strategy-in-the-treatment-of-stage-iii-non-small-cell-lung-cancer-patients-100603610","NCT07138755","The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n1. The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study\n2. Age range of 18-75 years old upon enrollment, both male and female are eligible\n3. Stage III NSCLC confirmed by histology or cytology (according to the International Union Against Cancer and the Joint American Committee on Cancer 8th edition TNM staging of lung cancer)\n4. It was clarified that surgical resection is not possible After MDT discussion,\n5. The main driver genes have no sensitive mutations (including EGFR, ALK, ROS1, MET, HER2, etc.)\n6. No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC\n7. According to RECIST v1.1, there is at least one measurable lesion, and according to RECIST v1.1, this lesion is suitable for repeated and accurate measurements\n8. There is sufficient organ function reserve to meet the needs of clinical research\n\nExclusion Criteria:\n\n1. There are any small cell carcinoma components present in the histopathology, as well as special types such as salivary gland type and SMARCA4 deficiency\n2. Except for NSCLC, the subjects had other malignant tumors within the 5 years prior to enrollment. Subjects with other tumors that have been cured by local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ, are not excluded\n3. Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation\n4. Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used to treat thrombocytopenia) within 2 weeks before the first administration; Received Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications within 1 week before the first administration\n5. Suffering from active autoimmune diseases that require systematic treatment within the past two years\n6. History of immunodeficiency; Individuals who test positive for HIV antibodies; Currently in long-term use of systemic corticosteroids or other immunosuppressants\n7. Subjects who are known to have active pulmonary tuberculosis (TB) and suspected of having TB need to undergo clinical examination to exclude them; Known active syphilis infection\n8. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n9. Previous or current non infectious pneumonia\u002Finterstitial lung disease requiring systemic corticosteroid therapy\n10. Serious infection occurred within 4 weeks prior to the first administration, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; Active infections that have received systemic anti infective therapy within 2 weeks prior to the first administration (excluding antiviral therapy for hepatitis B or C)\n11. Current active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 1000 copies\u002Fml (200IU\u002Fml) or above the detection limit)\n12. Tumor invasion or compression of important surrounding organs (such as aorta, heart and pericardium, superior vena cava, trachea, esophagus, etc.) or the risk of developing esophagotracheal fistula or esophageal pleural fistula; Tumor mediastinal lymph node metastasis invading the trachea and main bronchus with the risk of bronchial fistula\n13. History of myocarditis, cardiomyopathy, and malignant arrhythmia in the past\n14. Within 6 months prior to the first administration, there is a history of esophageal and gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding\n15. Any arterial thromboembolic event, NCI CTCAE 5.0 grade 3 or higher venous thromboembolic event, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy occurred within 6 months prior to the first administration; Currently, there is hypertension and after treatment with oral antihypertensive drugs, the systolic blood pressure is ≥ 160mmHg or the diastolic blood pressure is ≥ 100mmHg\n16. History of severe bleeding tendency or coagulation dysfunction\n17. Received a live vaccine within 30 days prior to the first administration, or planned to receive a live vaccine during the study period\n18. Known to be allergic to any component of any anti-tumor drug; Known history of severe hypersensitivity reactions to other monoclonal antibodies\n19. Known history of mental illness, drug abuse, alcoholism, or drug use\n20. Pregnant or lactating women\n21. Any past or current diseases, treatments, or laboratory abnormalities that may confuse the research results, affect the participants' full participation in the study, or may not be in the best interests of the participants\n22. Local or systemic diseases caused by non malignant tumors, or diseases or symptoms secondary to tumors, which can lead to higher medical risks and\u002For uncertainty in survival evaluation, such as tumor like leukemia reactions (white blood cell count\\>20 × 109\u002FL), cachexia manifestations (such as known weight loss of more than 10% in the first 3 months of screening), etc",{"count":191,"type":22},35,[25],"To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients",[28,195,196],"Sintilimab","Adaptive Radiotherapy",[198,199,196,200],"V20","stage III NSCLC","sintilimab","2026-03-20",{"date":174,"type":33},{"date":204,"type":33},"2025-08-29",{"date":206,"type":22},"2030-09",{"name":39,"class":40},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":78,"minAge":18,"maxAge":80,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":41},"100625428","a-real-world-study-comparing-the-efficacy-of-different-treatment-regimens-for-early-missed-abortion-100625428","NCT07422506","A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion","Inclusion Criteria:\n\n* ①Age 18-40 years old; ②Early pregnancy missed abortion confirmed by imaging and laboratory tests; ③All indicators of routine examinations before treatment are within the normal range, and there are no serious systemic diseases; ④No indications for emergency curettage; ⑤Good compliance, follow-up observation as required (prospective study).\n\nExclusion Criteria:\n\n* ①Contraindications to medical abortion; ②Those who are allergic to estrogen and have contraindications to the use of estrogen; ③Those who cannot be followed up according to the follow-up plan; ④Thromboembolic diseases, known or suspected history of breast cancer, hormone-dependent tumors, etc.; ⑤Vaginal bleeding exceeds the usual menstrual volume; ⑥Those with severe heart, liver and kidney diseases; ⑦Accompanied by serious internal and surgical diseases, malignant tumors or mental illnesses, and cannot cooperate.",{"count":215,"type":22},580,[52],"At present, there is no unified standard for the treatment of missed abortion in clinical practice. This study intends to collect clinical data of this type of disease to compare the efficacy of different treatments, and on this basis, presuppose the synergistic effect of different doses of estrogen in the process of drug induction, conduct statistical analysis of the efficacy, evaluate whether the treatment plan can achieve the therapeutic effect while reducing the occurrence of complications, and provide an effective basis for the subsequent clinical treatment of missed abortion.\n\nThis study is divided into two parts. The first part is a retrospective analysis to explore the differences between missed abortion surgery and drug treatment, clinical efficacy and reproductive outcomes; the second part is a prospective study to explore the effects of different doses of estrogen combined with surgery or drug abortion on the efficacy of missed abortion in early pregnancy, and explore the best clinical treatment method for missed abortion.",[219,220],"Missed Abortion","Early Pregnancy Failure","2026-02-12",{"date":223,"type":33},"2026-02-20",{"date":225,"type":33},"2024-01-01",{"date":227,"type":22},"2035-01-01",{"name":39,"class":40},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":235,"sex":78,"minAge":18,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":41},"100625382","investigating-the-association-between-diagnostic-and-therapeutic-management-models-and-prognosis-of-intrauterine-adhesions-based-on-a-large-scale-prospective-cohort-study-100625382","NCT07421908","Investigating the Association Between Diagnostic and Therapeutic Management Models and Prognosis of Intrauterine Adhesions Based on a Large-Scale Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with intrauterine adhesions diagnosed and treated in our hospital and the sub-central units of this project: aged 18-45 years old; The collection began after the ethical review was passed. A total of 5,000 cases were collected, and 2,000 cases were collected in this center.\n\nExclusion Criteria:\n\n* Abnormal ovarian function, male infertility, inability to cooperate with diagnosis and treatment and follow-up visits",true,"45 Years",{"count":50,"type":22},[52],"This research plan aims to explore a new diagnosis and treatment management model for intrauterine adhesions and verify its efficacy and feasibility through a multicenter real-world study. Intrauterine adhesions are a common gynecological disease that may affect women's fertility. The study will focus on several key issues:\n\n1. How do three-dimensional ultrasound image features reflect the diagnosis and prognosis of intrauterine adhesions;\n2. The effect of new diagnostic and treatment technologies (such as cold knife plowing technology and patented intrauterine stents) in preventing the recurrence of intrauterine adhesions\n3. The efficacy of traditional Chinese medicine prescriptions in promoting endometrial growth and preserving pregnancy;\n4. How to construct a postoperative infertility risk prediction model that combines multidimensional risk factors of traditional Chinese and Western medicine.\n\nTo achieve these goals, the study will:\n\n1. Establish four-dimensional ultrasound diagnostic evaluation standards to improve the accuracy of diagnosis;\n2. Build a large database and data cohort, standardize the diagnosis and treatment standards, and provide solid data support for the research;\n3. Evaluate the efficacy of the new model through real-world research, and compare the clinical efficacy of the new diagnosis and treatment model with the traditional diagnosis and treatment model;\n4. Construct and verify the postoperative infertility risk prediction model to provide clinicians with a visual display of risk prediction for clinical application.\n\nThis study is expected to provide a scientific basis for improving the treatment effect of intrauterine adhesions and reducing the infertility rate, and promote the standardization and standardization of the diagnosis and treatment model of combining traditional Chinese and Western medicine, bringing good news to more patients with intrauterine adhesions.",[109],[242,243,244,245,246],"Hysteroscopy","ploughing technique","cold scissors","Gland density","multi-center study","2026-02-11",{"date":249,"type":33},"2026-02-19",{"date":251,"type":33},"2025-03-01",{"date":253,"type":22},"2035-03-01",{"name":39,"class":40},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":235,"sex":78,"minAge":18,"maxAge":236,"enrollmentInfo":261,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":41},"100625381","a-prospective-multicenter-observational-real-world-study-of-retained-products-of-conception-100625381","NCT07421895","A Prospective Multicenter Observational Real-world Study of Retained Products of Conception","Inclusion Criteria:Clinical diagnosis of retained products of conception, and ultrasound indicated that the maximum diameter of the lesion ≥0.5cm.\n\nExclusion Criteria:1) There is active bleeding requiring immediate surgical intervention;2) combined with obvious infection;3) Combined with severe organ dysfunction, including coagulation dysfunction.",{"count":262,"type":22},600,"OBSERVATIONAL","The purpose of this study is to explore the optimal treatment strategy for retained products of pregnancy. Compared with surgical treatment, prospectively observe whether drug-assisted expectant management until the right time for surgery reduce the occurrence of intrauterine adhesions, and thus protect fertility.",[266,267],"Retained Products of Conception","RPOC",{"date":249,"type":33},{"date":270,"type":33},"2022-06-01",{"date":272,"type":22},"2032-12-31",{"name":39,"class":40},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":235,"sex":17,"minAge":18,"maxAge":281,"enrollmentInfo":282,"targetDuration":283,"studyType":263,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":41},"100622519","environmental-and-behavioral-factors-in-infertility-and-art-outcomes-100622519","NCT07384676","Environmental and Behavioral Factors in Infertility and ART Outcomes","A Large-Scale Prospective Cohort Study on the Association of Environmental Exposures and Behavioral Factors With Infertility and Assisted Reproductive Technology (ART) Success Rates","Inclusion Criteria:\n\n* A. Women aged 18 to 46 who use their own eggs; Men aged 18 to 55 who use their own sperm; B. Patients meeting the diagnostic criteria for infertility; C. Medical history clearly indicating the duration of persistent infertility; D. Voluntarily participating in the project and signing the informed consent form;\n\nExclusion Criteria:\n\n* A. The groups of artificial insemination patients with any of the following ARTs contraindications: a. The female has a sperm-egg combination disorder caused by tubal factors. b. The female has acute infections of the reproductive and urinary systems or sexually transmitted diseases. c. The female has genetic diseases, severe physical illnesses, or mental and psychological disorders. d. There is a history of giving birth to infants with congenital defects and it has been confirmed that the defect was caused by the female. e. The female has been exposed to teratogenic doses of radiation, toxins, or drugs and is in the active period. f. The female has bad habits such as alcoholism or drug abuse. B. The groups of first-generation and second-generation IVF patients with any of the following ARTs contraindications: a. Either of the parties providing gametes has acute infections of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism or drug abuse. b. Either of the parties providing gametes has been exposed to teratogenic doses of radiation, toxins, or drugs and is in the active period. c. The female partner of the recipient who provides eggs or embryos has acute infections of the reproductive and urinary systems and sexually transmitted diseases, or has bad habits such as alcoholism or drug abuse. d. The female has an unviable uterus or severe physical illnesses that cannot withstand pregnancy. C. No embryo transfer was performed after egg retrieval; D. More than 180 days have passed since egg retrieval and frozen embryo transfer was performed.","46 Years",{"count":50,"type":22},"18 Months","This large-scale study aims to understand how everyday environment and lifestyle may affect the success of fertility treatments like IVF. The main idea is that exposure to certain environmental chemicals (e.g., from plastics or air pollution) and personal habits (e.g., diet, stress) could be linked to whether these treatments result in a successful pregnancy and live birth.\n\nThe study will follow approximately 5,000 couples undergoing fertility treatment in Hunan, China. Participants will answer questionnaires about their health, lifestyle, and environment and provide small biological samples (like blood and urine) during their standard treatment process. Their treatment outcomes will be tracked anonymously.The goal is to identify factors that might lower the chances of treatment success. This knowledge could help future patients and doctors make informed decisions and could guide public health advice on reducing potential risks. The study has received ethical approval, and all participant information will be kept strictly confidential.",[286,60,287],"Environmental Exposure","Prospective Study","2026-01-26",{"date":290,"type":33},"2026-02-03",{"date":292,"type":33},"2024-12-01",{"date":294,"type":22},"2034-12-31",{"name":39,"class":40},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":124,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":4},"100611463","phase-4-antihypertensive-drug-selection-based-on-hemodynamic-phenotypes-100611463","NCT07240909","Antihypertensive Drug Selection Based on Hemodynamic Phenotypes","A Multicenter, Randomized, PROBE Trial on Antihypertensive Drug Selection Based on Hemodynamic Phenotypes Defined by Bioelectrical Impedance Analysis","HEMOPHENO","Inclusion Criteria:\n\n1. Aged ≥30 and \\\u003C80 years, regardless of gender;\n2. Confirmed diagnosis of hypertension meeting the criteria outlined in the 2024 Chinese Hypertension Guidelines: office blood pressure ≥140\u002F90 mmHg and home blood pressure ≥135\u002F85 mmHg;\n3. Mild to moderate hypertension, with office blood pressure ranging from 140-179\u002F90-109 mmHg;\n4. No prior use of antihypertensive medications;\n5. Voluntary participation in the study with written informed consent obtained.\n\nExclusion Criteria:\n\n1. Diagnosed or highly suspected secondary hypertension;\n2. Classified as mixed type according to hemodynamic typing;\n3. Allergy to the intended antihypertensive medications;\n4. Dysphagia;\n5. Pregnant or lactating women;\n6. Potential pregnancy plans during the trial period;\n7. Uncorrected electrolyte disturbances;\n8. Severe organ dysfunction;\n9. Comorbid conditions leading to inaccurate blood pressure measurement;\n10. Comorbid conditions or states unsuitable for noninvasive hemodynamic measurement via bioelectrical impedance;\n11. Comorbid conditions contraindicating or requiring caution with trial medications;\n12. Comorbid conditions affecting the absorption, distribution, metabolism, or excretion of trial drugs;\n13. Concurrent or planned use of medications contraindicated or requiring caution with trial drugs;\n14. Concurrent or planned use of medications interfering with trial outcomes;\n15. Clinician's assessment deems the patient unsuitable for the trial's antihypertensive regimen;\n16. Current participation in other clinical studies that may interfere with the conduct of this trial.","30 Years",{"count":306,"type":22},240,[308],"PHASE4","The goal of this clinical trial is to explore the clinical efficacy and safety of individualized antihypertensive medication guided by hemodynamic phenotyping. The main questions it aims to answer are:\n\n1. Does hemodynamics-based individualized antihypertensive therapy achieve better blood pressure control compared to guideline-based conventional therapy?\n2. Does hemodynamics-based individualized therapy have comparable safety to guideline-based conventional treatment? Researchers will compare hemodynamics-based individualized antihypertensive therapy to guideline-based conventional treatment to see if the former is better than the latter.\n\nParticipants will:\n\n1. Take hemodynamics-based individualized antihypertensive therapy or guideline-based conventional treatment every day for 8 weeks\n2. Visit the clinic once every 4 weeks for checkups and tests\n3. Keep a diary of their symptoms and any treatment",[311],"Hypertension",[313,314,315],"hypertension","anti-hypertensive therapy","Hemodynamics","2025-11-16",{"date":318,"type":33},"2025-11-21",{"date":320,"type":22},"2026-01",{"date":322,"type":22},"2026-12",{"name":39,"class":40},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":41},"100610708","early-phase-1-a-clinical-study-evaluating-the-safety-tolerability-preliminary-efficacy-and-immunogenicity-of-a-tumor-vaccine-injection-targeting-stressinducible-proteins-micab-in-combination-with-the-ag-regimen-in-patients-with-metastatic-pancreatic-cancer-100610708","NCT07231094","A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA\u002FB in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Histologically or cytologically confirmed unresectable metastatic pancreatic cancer;\n3. No prior systemic anti-tumor therapy for metastatic pancreatic cancer. Neoadjuvant or adjuvant therapy is permitted, provided no disease progression occurred within 6 months after the last administration;\n4. At least one measurable lesion according to RECIST v1.1 criteria;\n5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;\n6. Expected survival ≥6 months and ability to receive tumor vaccine and AG regimen treatment;\n7. Adequate organ and bone marrow function at screening, defined as follows:\n\n   Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL without granulocyte colony-stimulating factor support; Platelet count (PLT) ≥100 × 10⁹\u002FL without transfusion; Hemoglobin ≥90 g\u002FL; Serum creatinine ≤1.5 × upper limit of normal (ULN) or creatinine clearance ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault equation); Total bilirubin (BIL) ≤1.5 × ULN; Aspartate aminotransferase (AST\u002FSGOT) or alanine aminotransferase (ALT\u002FSGPT) ≤2.5 × ULN (≤5 × ULN for patients with liver metastases); Coagulation parameters: prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 × ULN; international normalized ratio (INR) ≤1.5 × ULN.\n8. Left ventricular ejection fraction (LVEF) ≥50% as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan;\n9. Willingness and ability to provide written informed consent and comply with protocol-specified visits and procedures;\n10. Fertile patients (male and female) must agree to use reliable contraception (hormonal, barrier methods, or abstinence) during the study.\n\nExclusion Criteria:\n\n1. Active or prior autoimmune disease, immunodeficiency, or primary immunodeficiency (including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis). Exceptions include:\n\n   Autoimmune hypothyroidism controlled with thyroid hormone replacement therapy; Well-controlled type 1 diabetes managed with insulin; Eczema, psoriasis, neurodermatitis, or vitiligo limited to skin involvement, with rash \\\u003C10% of body surface area, stable at baseline, requiring only low-potency topical corticosteroids, and no acute exacerbations within the past 12 months.\n2. Receipt of systemic immunosuppressive drugs (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-TNF agents, etc.) within 2 weeks before initiation of study treatment, or anticipated need during the study, except in the following cases:\n\n   Short-term, low-dose systemic immunosuppression or a single pulse dose (e.g., glucocorticoids for 48 hours due to contrast allergy); Use of mineralocorticoids (e.g., fludrocortisone), inhaled corticosteroids, or low-dose corticosteroids (≤10 mg\u002Fday prednisone or equivalent) for chronic obstructive pulmonary disease\u002Fasthma, or low-dose corticosteroids for orthostatic hypotension\u002Fadrenal insufficiency.\n3. History of other malignancies within 5 years prior to screening, except for cancers with negligible risk of metastasis or death (5-year recurrence-free survival \\>90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I endometrial cancer.\n4. Severe cardiovascular, cerebrovascular, gastrointestinal, or hepatic disease, including:\n\n   Significant cardiovascular disease within 3 months prior to treatment (e.g., New York Heart Association \\[NYHA\\] Class III or IV heart failure, myocardial infarction, or cerebrovascular accident), unstable arrhythmias, or unstable angina; Severe colon or rectal disease, or postoperative complications resulting in grade ≥2 diarrhea, intestinal obstruction, or incomplete obstruction; Clinically significant liver disease, including active viral hepatitis, alcoholic hepatitis or other hepatitis, cirrhosis, hereditary liver disease, or investigator-assessed current alcohol abuse.\n5. Active infections requiring treatment, including active HBV or HCV infection; known HIV infection or history of AIDS; active tuberculosis.\n6. Toxicities from prior anti-tumor therapies not resolved to grade ≤2 per NCI-CTCAE v5.0 (or higher version) or baseline, except for alopecia and skin hyperpigmentation (any grade allowed).\n7. Receipt of a live vaccine within 28 days prior to the first study treatment or planned receipt of a live vaccine during the study.\n8. Positive serum pregnancy test or lactating women.\n9. History of severe hypersensitivity to biologic products.\n10. Any other condition that, in the opinion of the investigator, renders the subject unsuitable for study participation.",{"count":331,"type":22},13,[333],"EARLY_PHASE1","Study design:\n\nThis is a single-arm, open-label, dose-escalation and dose-expansion clinical study to evaluate the safety and efficacy of multiple doses of SapDM275 tumor vaccine injection in combination with the AG regimen for the treatment of patients with metastatic pancreatic cancer who have not received prior systemic anti-cancer therapy and are planned to receive AG as first-line treatment.\n\nTreatment must be initiated within 7 days after enrollment. Patients will receive intramuscular injections of SapDM275 tumor vaccine combined with AG regimen until the occurrence of any of the following: disease progression, intolerable toxicity, death (whichever occurs first), the investigator's assessment that the subject is no longer suitable for further treatment, or withdrawal of consent by the subject.",[336],"Pancreatic Cancer Metastatic","2025-11-13",{"date":339,"type":33},"2025-11-17",{"date":341,"type":22},"2025-11",{"date":343,"type":22},"2028-12",{"name":39,"class":40},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":41},"100602415","preliminary-clinical-study-on-the-effect-of-bacillus-subtilis-on-the-efficacy-of-infliximab-in-patients-with-crohns-disease-100602415","NCT07123207","Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease","The Impact of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease: a Multicenter, Randomized, Single-blind, Blank-controlled Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years old, ≤ 75 years old;\n2. Patients clinically diagnosed with Crohn's disease shall refer to the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023) for diagnostic criteria;\n3. Patients receiving treatment with Infliximab;\n4. The patient is currently in the clinical active stage(CDAI≥150 or SES-CD≥3);\n5. Agree to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are not eligible for inclusion in this study.\n\n1. Patients with ALT or AST exceeding the normal upper limit by more than twice, and TBIL exceeding the normal upper limit by more than twice;\n2. Patients with creatinine clearance rate less than 60ml\u002Fmin;\n3. Patients with severe active infections in the intestines or other areas that require the use of antibiotics or antiviral drugs;\n4. Patients with intestinal tuberculosis, other chronic intestinal infectious diseases, and intestinal malignant tumors;\n5. Pregnant and lactating women;\n6. The fasting blood glucose of patients with diabetes or screening period exceeds 7.0mmol\u002FL or glycosylated hemoglobin exceeds 6.5%;\n7. Merge patients with severe mental illness, drug use, alcohol abuse, etc. who are unable to cooperate with the study;\n8. Have participated in any other clinical research within the first month prior to enrollment;\n9. The researcher determined that any other disease or condition is not suitable for patients participating in this study.",{"count":353,"type":22},24,[52],"The goal of this clinical trial is to evaluate the effect of supplementing Bacillus subtilis compared to the control group on the efficacy of Infliximab in patients with Crohn's disease, and to summarize the role of supplementing Bacillus subtilis in the treatment of CD patients.\n\nParticipants will be randomized into two groups: the Bacillus subtilis supplementation group and the control group. The patients in the Bacillus subtilis supplementation group received oral Bacillus subtilis capsules for 12 weeks. The control group did not receive additional intervention. Follow up once a week, and after the study, patients will come to the hospital to finish the evaluation indicators.",[357],"Mild to Severe Crohns Disease",[359,360],"Infliximab","Bacillus subtilis","2025-08-07",{"date":363,"type":33},"2025-08-14",{"date":365,"type":33},"2025-08-04",{"date":367,"type":22},"2027-01-30",{"name":39,"class":40},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":378,"conditions":379,"keywords":383,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":394,"locationsCount":41},"100600131","establishment-of-a-classification-system-and-postoperative-risk-warning-model-for-patients-undergoing-bariatric-metabolic-surgery-for-severe-obesity-100600131","NCT07093502","Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe Obesity","Inclusion Criteria:\n\n* Patients who meet the clinical indications for bariatric\u002Fmetabolic surgery;\n\n  * Adults aged 18 to 50 years; ③ Stable body weight (change within ±5% over the past 3 months); ④ Undergoing either laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB).\n\nExclusion Criteria:\n\n* ① Patients with conditions affecting the immune or metabolic systems (e.g., endocrine disorders such as untreated hypothyroidism\u002Fhyperthyroidism, cancer);\n\n  * Patients with renal or hepatic impairment;\n\n    * Patients who have taken medications that may affect metabolism within the past 3 months (e.g., weight-loss drugs, asthma medications, psychiatric medications, corticosteroids);\n\n      * Patients who have previously undergone bariatric surgery and are undergoing revisional surgery; ⑤ Patients with psychiatric disorders, especially those with comorbid behavioral or personality disorders (e.g., binge eating disorder);\n\n        * Patients currently participating in other clinical studies that may conflict with this study or those who refuse to sign the informed consent form.","50 Years",{"count":377,"type":22},2000,"This study aims to establish a classification system for patients undergoing metabolic surgery for severe obesity by constructing a prospective cohort of 2,000 patients and collecting clinical and biological data at multiple time points before and after surgery. By analyzing clinical, laboratory, and multi-omics characteristics, the study will identify indicators associated with postoperative adverse events and develop a risk warning model using machine learning algorithms. Ultimately, an intelligent digital system will be developed based on the classification criteria and risk model, integrating surgical classification and risk alert functions to provide real-time feedback, supporting clinicians and patients in optimizing postoperative treatment and risk management.",[380,381,382],"Obesity","Bariatric Surgery","Bariatric Surgery (Sleeve Gastrectomy )",[384,385,386,387],"Severe obesity","bariatric surgery","Classification System","Postoperative Risk Warning Model","2025-07-29",{"date":390,"type":33},"2025-07-30",{"date":68,"type":33},{"date":393,"type":22},"2035-12-31",{"name":39,"class":40},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":402,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":413,"leadSponsor":415,"locationsCount":41},"100600115","value-of-ius-in-predicting-vedolizumab-efficacy-and-assessing-transmural-healing-in-early-crohns-disease-a-multicenter-prospective-study-100600115","NCT07093294","Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study","Value of Intestinal Ultrasound in Predicting Vedolizumab Response and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years;\n* Early CD patients (disease duration ≤18 months, biologic-naïve and treatment-naïve for advanced therapies, without complications such as fistulas or strictures)\n* Vedolizumab therapy is proposed to be applied within 1 month after baseline endoscopy and intestinal ultrasound,;\n* No history of intestinal surgery;\n* Clearly understand, voluntarily participate in the study, and sign an informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to vedolizumab: allergy, active tuberculosis or other active infections, moderate-to-severe heart failure (NYHA grade III\u002F IV), demyelinating lesions of the nervous system, live vaccination within the last 3 months, pregnancy and lactation;\n* Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;\n* Hypersensitivity to the components of SonoVue contrast media.",{"count":403,"type":22},60,"Crohn's disease(CD) is a chronic nonspecific inflammatory disease of the intestinal tract whose etiology is not yet fully understood,characterized by transmural inflammation , can present with serious complications such as intestinal obstruction, perforation, abdominal abscesses, and fistulae. In recent years, the incidence of CD has increased rapidly, causing a heavy social and economic burden. Currently, the main therapeutic drugs for CD include aminosalicylic acid preparations, glucocorticoids, immunosuppressants, and biological agents. With the development of medical technology, small molecule preparations have begun to be applied to moderate-to-severe Crohn's disease, providing new treatment options for patients with Crohn's disease.\n\nVedolizumab, a humanized monoclonal antibody.the GEMINI study demonstrated its superior efficacy over placebo in inducing and maintaining clinical remission. And the VERSIFY study confirmed its advantage in achieving mucosal healing, with a transmural healing rate of 29.1% at week 52.\n\nIntestinal ultrasound is a noninvasive, reproducible, convenient, and inexpensive test that can greatly increase the frequency of assessing treatment response and speed up the clinical decision-making process.The 2019 ECCO-ESGAR guidelines recommend intestinal ultrasound for disease monitoring in patients with CD. Multiple studies have shown that most ultrasound markers normalize within 12 weeks of treatment initiation, and in particular, normalization of bowel wall thickness is highly correlated with clinical response at 12 weeks. There are no validated indicators to predict the efficacy of upadacitinib treatment in patients with moderate-to-severe CD in the currently available studies.\n\nCurrently, there are no national or international studies in which intestinal ultrasound predicts the efficacy and assesses the transmural healing of vedolizumab therapy. Therefore, we propose for the first time that intestinal ultrasound be used as a method to predict the response to vedolizumab in early CD patients, with the aim of providing evidence to guide the development of individualized treatment plans.",[406,407,408,409],"Crohn Disease (CD)","Vedolizumab","Intestinal Ultrasound","Predictor","2025-07-22",{"date":390,"type":33},{"date":94,"type":33},{"date":414,"type":22},"2027-09-30",{"name":39,"class":40},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":425,"studyType":263,"phases":4,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":41},"100596197","risk-factors-for-microvascular-obstruction-post-emergency-pci-in-ami-patients-100596197","NCT07042321","Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients","Triglyceride Glucol Index for Predicting the Value of No-Reflow in Patients Undergoing Emergency PCI for Acute Myocardial Infarction","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* STEMI symptom onset time \\\u003C 12 hours.\n* STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias.\n* Very high-risk NSTEMI; undergoing emergency PCI treatment.\n* Voluntary signed informed consent form.\n\nExclusion Criteria:\n\n* Non-obstructive acute myocardial infarction.\n* Severe chronic kidney disease (defined as estimated glomerular filtration rate \\\u003C20 mL\u002Fmin per 1.73 m²).\n* Pregnant women or those planning to become pregnant.\n* Failure of emergency PCI.\n* Unclear CMR images",{"count":424,"type":22},300,"1 Month","The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are:\n\n* How does the TyG index correlate with the early detection of MVO?\n* What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.",[428],"Acute Myocardial Infarction (AMI)","2025-06-29",{"date":431,"type":33},"2025-07-02",{"date":433,"type":33},"2024-06-01",{"date":435,"type":22},"2025-08-31",{"name":39,"class":40},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":454,"leadSponsor":455,"locationsCount":41},"100595949","a-multicenter-prospective-randomized-controlled-clinical-study-on-the-effect-of-hysteroscopic-uterine-septum-resection-on-the-natural-pregnancy-outcomes-in-patients-with-non-recurrent-spontaneous-abortion-100595949","NCT07039097","A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on the Natural Pregnancy Outcomes in Patients With Non-recurrent Spontaneous Abortion","Inclusion Criteria:\n\n* (1) The patient meets the 2024 ASRM diagnostic criteria for uterine septate after three-dimensional color Doppler ultrasound examination; (2) The patient may have never been pregnant, or may have a history of live birth, one biochemical pregnancy, or one fetal arrest. The patient may also be an infertile patient who wishes to conceive naturally, such as a patient with hydrosalpinx and laparoscopic stoma, or a patient whose infertility factors can be treated; (3) The patient is between 20 and 40 years old; (4) The patient plans to try to conceive naturally to achieve the desire to have a baby; (5) The patient has normal ovarian reserve function (AMH\\>1.1ng\u002Fml, FSH\\\u003C12U\u002FL on the 2nd to 5th day of menstruation); (6) The male's semen is generally normal; (7) The patient signs the informed consent form and is able to accept and adhere to treatment and follow-up. Patients in the control group can undergo hysteroscopy or hystero-laparoscopy to treat other problems, but septal resection is not performed.\n\nExclusion Criteria:\n\n* (1) Recurrent miscarriage; (2) Patients with intramural uterine myoma larger than 3 cm, moderate to severe intrauterine adhesions; (3) Uncontrolled endocrine disorders, such as abnormal thyroid function (FT3, FT4 abnormal), hyperprolactinemia (greater than 2 times the upper limit of normal), uncontrolled endometrial hyperplasia, EIN or malignant lesions, acute inflammation of the reproductive system, coagulation dysfunction, etc.; if combined with endometrial polyps or submucosal myoma, patients can still be included in the group after resection; (4) Patients with adenomyosis (uterine body\\>50 days of pregnancy), chocolate cysts with a diameter of\\>4 cm, or severe dysmenorrhea and clear DIE lesions (diameter\\>1 cm) can be palpated during gynecological triple examination; (5) Untreated bilateral hydrosalpinx or obstruction; (6) Other important organ diseases and other surgical contraindications or relative contraindications. Other situations that are not suitable for assisted reproductive treatment. Those who have participated in other clinical research (within the past three months); (7) Those who are assessed to need IVF (e.g., those whose fallopian tubes cannot be cleared, or whose ovulation dysfunction cannot be treated with medication, etc.).",{"count":444,"type":22},418,[52],"The study aims to compare the effects of transcervical resection of septa (TCRS) and expectant management on the natural pregnancy outcomes of patients with septate uterus without recurrent abortion, also covering the treatment of other infertility factors in infertile patients who aim at natural conception. The research attempts to answer whether TCRS can improve the live birth rate, pregnancy rate and pregnancy outcomes for septate uterus patients planning natural pregnancy, so as to provide evidence-based medical evidence for the selection of clinical treatment methods for such patients.",[86],[88,449],"Natural Pregnancy","2025-06-18",{"date":452,"type":33},"2025-06-26",{"date":94,"type":33},{"date":96,"type":22},{"name":39,"class":40},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":463,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":475,"locationsCount":41},"100595608","ius-predicts-guselkumab-efficacy-in-patients-with-moderate-to-severe-crohns-diseasea-prospective-study-100595608","NCT07034664","IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study","Intestinal Ultrasound Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study","Inclusion Criteria:\n\nAge ≥ 18 years and ≤ 80 years;\n\n* Patients with newly diagnosed or relapsed moderate to severe Crohn's disease;\n* Guselkumab therapy is proposed to be applied within 1 month after baseline endoscopy and intestinal ultrasound;\n* No history of abdominal surgery;\n* Clearly understand, voluntarily participate in the study, and sign an informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to Guselkumab: allergy, active tuberculosis or other active infections, and comorbidities such as severe liver dysfunction;\n* Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;\n* Hypersensitivity to the components of SonoVue contrast media.",{"count":464,"type":22},50,"Crohn's disease (CD) is a chronic non-specific intestinal inflammatory disease with incompletely clarified etiology, which can involve multiple organs and systems , and is prone to severe complications such as intestinal obstruction, perforation, and fistula.Currently, the main therapeutic drugs for CD include aminosalicylates, glucocorticoids, immunosuppressants, biological agents, etc. With the development of medical technology, biological agents have begun to be applied to moderate-to-severe Crohn's disease, providing new treatment options for patients with moderate-to-severe Crohn's disease.\n\nGuselkumab is a selective inhibitor of the interleukin-23 (IL-23) p19 subunit.The GALAXI2 and GALAXI3 studies demonstrated that guselkumab can better achieve the therapeutic goal of mucosal healing. The clinical remission rates of guselkumab at week 12 were 47.1% and 47.1%, respectively, and the endoscopic response rates were 37.7% and 36.2%, respectively .\n\nIntestinal ultrasound lUsnoninvasive, reproducible, convenient, and inexpensive test that can greatly increase the frequency of assessing treatment response and speed up the clinical decision-making process.The 2019 ECCO-ESGAR guidelines recommend intestinalultrasound for disease monitoring in patients with CD. There are no validated indicators to predict the efficacy of guselkumab treatment in patients with moderate-to-severe CD in the currently available studies.\n\nCurrently, there are no national orinternational studies in which intestinal ultrasound predicts the efficacy of guselkumab therapy. Therefore, we propose for the first time that intestinal ultrasound be used as a method to predict the response to guselkumab in CD patients, with the aiproviding evidence to guide the development of individualized treatment plans.",[467,468,408,409],"Crohn's Disease","Guselkumab","2025-06-15",{"date":471,"type":33},"2025-06-24",{"date":473,"type":33},"2025-06-16",{"date":414,"type":22},{"name":39,"class":40},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":235,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":500,"locationsCount":41},"100500132","clinical-research-on-a-novel-deep-learning-based-system-in-mediastinal-endoscopic-ultrasound-scanning-100500132","NCT05792280","Clinical Research on a Novel Deep-learning Based System in Mediastinal Endoscopic Ultrasound Scanning","Clinical Research on Navigation and Quality Control System of Mediastinal Ultrasound Endoscopy Based on Deep Learning","Inclusion Criteria:\n\n* 1\\. Age ≥18 years old, \\\u003C80 years old 2.Patients who need endoscopic ultrasonography; 3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria cannot be selected for this trial:\n\nFirst. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography:\n\n1. Poor physical condition, including hemoglobin ≤8.0g\u002Fdl, severe cardiopulmonary insufficiency, etc.\n2. Anesthesia assessment failed\n3. Pregnancy or breastfeeding\n4. In the acute stage of chemical and corrosive injury, it is very easy to cause perforation\n5. Recent acute coronary syndrome or clinically unstable ischemic heart attack\n6. Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\\> 90mmHg),patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome.\n\nSecond. Disagree to participate in this study.\n\nThird. There are other problems that do not meet the requirements of this research or that affect the results of the research:\n\n1. Mediastinal lesions have previously undergone surgery or radiotherapy and chemotherapy;\n2. Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.",{"count":484,"type":22},180,[52],"The goal of this clinical trial is to develop and verify the auxiliary role of the artificial intelligence system in mediastinal ultrasound endoscopic scanning. The main questions it aims to answer are as follows: 1.The comparison of the image recognition accuracy between the artificial intelligence system and the ultrasound endoscopist; 2. Whether the artificial intelligence system can improve the integrity and efficiency of the mediastinum scanning for the ultrasound endoscopist. Participants will undergo mediastinal EUS with or without the assistance of the artificial intelligence system.",[488],"Mediastinum Disease",[490,491,492,493],"EUS","AI","Quality Control","training","2025-03-10",{"date":496,"type":33},"2025-03-13",{"date":113,"type":33},{"date":499,"type":22},"2025-04-10",{"name":39,"class":40},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":235,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":41},"100500131","clinical-research-on-a-novel-deep-learning-based-system-in-pancreatic-endoscopic-ultrasound-scanning-100500131","NCT05792267","Clinical Research on a Novel Deep-learning Based System in Pancreatic Endoscopic Ultrasound Scanning","Clinical Research on Navigation and Quality Control System of Pancreatic Ultrasound Endoscopy Based on Deep Learning","Inclusion Criteria:\n\n* 1\\. Age ≥18 years old, \\\u003C80 years old 2.Patients who need endoscopic ultrasonography of pancreas; 3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria cannot be selected for this trial:\n\nFirst. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography:\n\n1. Poor physical condition, including hemoglobin ≤8.0g\u002Fdl, severe cardiopulmonary insufficiency, etc.\n2. Anesthesia assessment failed\n3. Pregnancy or breastfeeding\n4. In the acute stage of chemical and corrosive injury, it is very easy to cause perforation\n5. Recent acute coronary syndrome or clinically unstable ischemic heart attack\n6. Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\\> 90mmHg),patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome.\n\nSecond. Disagree to participate in this study.\n\nThird. There are other problems that do not meet the requirements of this research or that affect the results of the research:\n\n1. Pancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand;\n2. Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.",{"count":105,"type":22},[52],"The goal of this clinical trial is to develop and verify the auxiliary role of the artificial intelligence system in pancreatic ultrasound endoscopic scanning.The main questions it aims to answer are as follows: 1.The comparison of the image recognition accuracy between the artificial intelligence system and the ultrasound endoscopist; 2. Whether the artificial intelligence system can improve the efficiency of the pancreatic scanning for the ultrasound endoscopist. Participants will undergo pancreatic EUS with or without the assistance of the artificial intelligence system.",[512],"Pancreatic Disease","2025-02-07",{"date":515,"type":33},"2025-02-12",{"date":113,"type":33},{"date":518,"type":22},"2025-06-30",{"name":39,"class":40},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":235,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":41},"100576810","validation-of-an-ai-assisted-pancreatic-eus-system-for-training-improvement-a-prospective-multi-center-randomized-trial-100576810","NCT06790134","Validation of an AI-Assisted Pancreatic EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial","Inclusion Criteria:\n\n1\\. Age ≥18 years old, \\\u003C80 years old 2.Patients who need endoscopic ultrasonography of pancreas; 3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria cannot be selected for this trial:\n\nFirst. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography:\n\nPoor physical condition, including hemoglobin ≤8.0g\u002Fdl, severe cardiopulmonary insufficiency, etc. Anesthesia assessment failed Pregnancy or breastfeeding In the acute stage of chemical and corrosive injury, it is very easy to cause perforation Recent acute coronary syndrome or clinically unstable ischemic heart attack Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\\> 90mmHg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome.\n\nSecond. Disagree to participate in this study.\n\nThird. There are other problems that do not meet the requirements of this research or that affect the results of the research:\n\nPancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand; Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.",{"count":105,"type":22},[52],"The goal of this clinical trial is to verify the auxiliary role of the artificial intelligence (AI) system in pancreatic endoscopic ultrasound (EUS) scans. The main questions it aims to answer are as follows:\n\n1. A comparison of the image recognition accuracy between the AI system and EUS endoscopists.\n2. Whether the AI system can improve the quality of scans for EUS endoscopists. Participants will conduct EUS scanning with or without the assistance of the AI system.",[530],"Pancreatic Diseases","2025-01-17",{"date":533,"type":33},"2025-01-23",{"date":535,"type":22},"2025-01-15",{"date":537,"type":22},"2026-03-30",{"name":39,"class":40},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":235,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":546,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":552,"leadSponsor":554,"locationsCount":41},"100576808","validation-of-an-ai-assisted-mediastinal-eus-system-for-training-improvement-a-prospective-multi-center-randomized-trial-100576808","NCT06790108","Validation of an AI-Assisted Mediastinal EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial","Inclusion Criteria:\n\n1\\. Age ≥18 years old, \\\u003C80 years old 2.Patients who need endoscopic ultrasonography; 3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria cannot be selected for this trial:\n\nFirst. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography:\n\nPoor physical condition, including hemoglobin ≤8.0g\u002Fdl, severe cardiopulmonary insufficiency, etc. Anesthesia assessment failed Pregnancy or breastfeeding In the acute stage of chemical and corrosive injury, it is very easy to cause perforation Recent acute coronary syndrome or clinically unstable ischemic heart attack Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\\> 90mmHg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome.\n\nSecond. Disagree to participate in this study.\n\nThird. There are other problems that do not meet the requirements of this research or that affect the results of the research:\n\n1. Mediastinal lesions have previously undergone surgery or radiotherapy and chemotherapy;\n2. Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.",{"count":105,"type":22},[52],"The goal of this clinical trial is to verify the auxiliary role of the artificial intelligence (AI) system in mediastinal endoscopic ultrasound (EUS) scans. The main questions it aims to answer are as follows:\n\n1. A comparison of the image recognition accuracy between the AI system and EUS endoscopists.\n2. Whether the AI system can improve the quality of mediastinal scans for EUS endoscopists.\n\nParticipants will conduct mediastinal EUS with or without the assistance of the AI system.",[549],"Mediastinal Disease",{"date":533,"type":33},{"date":535,"type":22},{"date":553,"type":22},"2026-06-30",{"name":39,"class":40},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":41},"100567540","correlation-of-blood-serum-renalase-and-microcirculation-obstruction-in-patients-with-acute-myocardial-infarction-after-primary-percutaneous-coronary-intervention-100567540","NCT06669520","Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. STEMI symptom onset time \\\u003C 12 hours;\n3. STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias;\n4. High-risk NSTEMI;\n5. Emergency PCI;\n6. Voluntary informed consent.\n\nExclusion Criteria:\n\n1. Non-obstructive acute myocardial infarction;\n2. Severe chronic kidney disease (defined as estimated glomerular filtration rate \\\u003C 20 mL\u002Fmin per 1.73 m²);\n3. Life expectancy \\\u003C 1 year;\n4. Pregnant or planning to become pregnant;\n5. Emergency PCI failure.",{"count":105,"type":22},"This research will explore the association between blood serum renalase and microcirculation obstruction in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). The investigators aim to identify potential risk factors for microcirculation obstruction in AMI patients after PPCI.",[564],"Acute Myocardial Infarction","2024-10-30",{"date":567,"type":33},"2024-11-01",{"date":569,"type":33},"2024-08-01",{"date":571,"type":22},"2025-10-01",{"name":39,"class":40},""]